Due to the increasing demand since the beginning of the pandemic for mRNA Covid-19 vaccines formulated with Lipid NanoParticle (LNP) delivery systems, CordenPharma has been continuously investing in expanded lipid supply chain at our facilities in Switzerland, France and Colorado.
 
LNP delivery systems not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play an important role as adjuvants in vaccine reactogenicity.
 
In order to accommodate this significant increase in market demand, CordenPharma has announced another major capital expenditure initiative, in addition to substantial investments in the past, which further enhances its lipid purification capacity in CordenPharma Colorado.
 
The expansion includes additional production lines ready to be incorporated into the lipid manufacturing process as early as April 2021, confirming the company’s position in both custom and Standard Lipids supply. By the end of July 2021, this investment will significantly decrease CordenPharma’s lipid shipment delivery time.
 
CEO & president Dr. Michael Quirmbach commented, “CordenPharma is proud to contribute this major capital expansion to increase important lipid production for the global market. We have drawn upon longstanding expertise in specialized lipids to create an even stronger integrated network of facilities to support current and future projects.”